Jehangir Hospital joins Clinerion’s Patient Network Explorer
Jehangir Hospital, along with its research arm Jehangir Clinical Development Centre (JCDC), is bringing its patients access to international clinical trials by joining Clinerion’s Patient Network Explorer platform. JCDC is the research arm of Jehangir Hospital, Pune, India. The hospital has over 350 beds, servicing patients throughout Pune and beyond. It has a wide range of disease-area specializations, including, but not limited to: cardiology, oncology, endocrinology, pediatrics, rheumatology, dermatology and infectious diseases. JCDC has over 60 principal investigators and conducts on average 25-30 clinical studies at any point of time.
Clinerion’s Patient Network Explorer helps partner hospitals be visible to pharmaceutical companies seeking suitable patients and sites for their clinical trials. Queries based on trial protocols may be sent to partners to assess the count of eligible patients in their electronic health records. All patient data is de-identified and remains under the control of the hospital and inside its IT infrastructure. However, Clinerion’s patented technology also enables authorized trial staff at the hospital to re-identify the patient for the purpose of trial recruitment.
“We at JCDC are delighted about partnering with Clinerion as there is an ideal alignment of Clinerion’s innovative technology and our clinical research expertise,” says Pathik Divate, CEO of the JCDC. “We are excited about harnessing the power of this technology to leverage our diverse patient population and bring in further efficiency in patient recruitment.”
“The population of India is significantly under-represented when it comes to participation in clinical research. Patient Network Explorer can cut a path through the forest, leading sponsors to the institutions and clinicians who can support clinical trials at an international level of expertise and facilities. This collaboration with Jehangir is just the first step in enabling a global population of eligible patients which reflects the diversity of the world, itself,” says Ian Rentsch, CEO of Clinerion.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
